Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 16p13 11 Microdeletion Syndrome C4304596
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 16p13 11 Microdeletion Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
16p13 11 Microdeletion Syndrome C4304596
A rare chromosomal deletion where a portion of chromosome 16 is missing. It may be associated with developmental delays, intellectual disability, and sometimes congenital anomalies. Management focuses on supportive care and addressing individual needs.
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
16p13 11 Microdeletion Syndrome C4304596
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
16p13 11 Microdeletion Syndrome C4304596
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
16p13 11 Microdeletion Syndrome C4304596
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
16p13 11 Microdeletion Syndrome C4304596
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p13 11 Microdeletion Syndrome C4304596
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p13 11 Microdeletion Syndrome C4304596
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 16p13-11-microdeletion-syndrome-C4304596 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p13 11 Microdeletion Syndrome C4304596 | Discriminating power |
|---|---|---|---|
| Salt-wasting or adrenal crisis | May occur, especially in infancy, with cortisol and often aldosterone deficiency. | Not a typical feature of this chromosomal condition. | High |
| Genital or sex-hormone findings | Androgen excess may cause atypical genitalia or later virilization. | Not characteristically driven by adrenal androgen excess. | High |
| Developmental delay or intellectual disability | Not the primary expected feature when hormone treatment is adequate. | May be associated, with variable severity and other congenital anomalies. | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Infant with suspected adrenal crisis
Cortisol deficiency and possible salt wasting point toward 21-hydroxylase-deficient CAH.
High
Atypical genitalia with androgen excess
Disordered adrenal steroid production is a leading consideration.
High
Abnormal newborn steroid screen
An abnormal screen is a finding, not a diagnosis, and needs confirmatory endocrine testing.
Moderate
Choose 16p13 11 Microdeletion Syndrome C4304596 when
Developmental delay with congenital anomalies
A chromosomal microdeletion is more consistent than primary adrenal disease.
Moderate
Family history of a known 16p13.11 deletion
Targeted genetic evaluation is appropriate; penetrance and features can vary.
Moderate
Normal endocrine evaluation but unexplained neurodevelopment
Chromosomal microarray may be considered after clinical assessment.
Low
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p13 11 Microdeletion Syndrome C4304596 | Interpretation |
|---|---|---|---|
| Adrenal steroid profile | Pattern may suggest 21-hydroxylase deficiency; exact cutoffs are not stated here. | No characteristic adrenal steroid abnormality is established. | Abnormal results require specialist confirmation and do not by themselves prove the diagnosis. |
| CYP21A2 genetic testing | Pathogenic variants may support the diagnosis when interpreted with biochemistry. | Not the primary test for a chromosome 16 deletion. | Genetic results should be correlated with phenotype and laboratory findings. |
| Chromosomal microarray | Not expected to identify the enzymatic disorder. | May detect a 16p13.11 deletion when present. | A deletion finding needs clinical correlation because effects can be variable. |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Often manageable as a chronic endocrine condition, but adrenal crisis can be serious.
- Factors
- Hormone control, crisis prevention, growth, and puberty monitoring.
16p13 11 Microdeletion Syndrome C4304596
- Outcome
- Variable; developmental and congenital features may persist and need support.
- Factors
- Deletion size, associated anomalies, and available therapies are not fully established here.
Time frame: Both are generally lifelong; exact outcomes cannot be predicted from these data.
Diagnosis confirmation, specialist follow-up, and individualized complications matter.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal insufficiency | A recognized risk, including possible life-threatening crisis. Not an established typical complication from the supplied description. Urgent care is needed for suspected crisis; this comparison does not provide treatment doses. |
| Growth and puberty effects | Hormone imbalance may affect growth and pubertal development. Growth effects are not specifically established here. Monitoring should be individualized by a clinician. |
| Neurodevelopmental impairment | Not the core complication described. Developmental delay or intellectual disability may occur. Severity and associated anomalies vary; supportive needs differ. |
Patient education highlights
- HighEmergency recognition
For suspected CAH, families should know warning signs of adrenal crisis and seek urgent care. This is not typical of the microdeletion.
- MediumLifelong versus supportive care
CAH generally needs ongoing hormone replacement; microdeletion care focuses on individual developmental and medical needs.
- MediumGenetic counseling
Both can be inherited or genetic, but inheritance patterns and testing differ. A genetics clinician should explain results.